Edesa Biotech announces $25 million public offering

Edesa Biotech has priced an underwritten public offering expected to raise approximately $25 million in gross proceeds. The offering includes 3,870,500 common shares with accompanying warrants and pre-funded warrants for up to 675,000 common shares.

The common share warrants have an exercise price of $7.50 and are set to expire either 18 months from issuance or 30 days after the company announces Phase 2 topline data for its vitiligo treatment, EB06. Guggenheim Securities is serving as the sole book-runner for the deal, which is expected to close around August 21, 2026. The company intends to use the net proceeds for general corporate purposes, including R&D, manufacturing, and working capital.

In separate corporate news, Belite Bio announced it will present data from its Phase 3 Dragon Study regarding Tinlarebant for Stargardt disease at upcoming medical congresses in Switzerland and Australia. Additionally, BioLab Holdings has entered a strategic partnership with mimiX AWC to add FastSkin autologous wound care technology to its portfolio. Synergy CHC Corp. reported receiving a notice from Nasdaq indicating it is not in compliance with listing rules due to delayed quarterly report filings.